COVID-19 pneumonia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From December 2014 to June 2026, FDA received 11,733 adverse event reports that record the MedDRA preferred term COVID-19 pneumonia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 527 reports in the 12 months to June 2026 and 885 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 955 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 527 (under 0.1%) record this term. Reports for male patients were 44.9% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 93 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term COVID-19 pneumonia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		136
Actemra	Interleukin-6 receptor antagonist	70
Adalimumab	Tumor necrosis factor blocker	76
Allopurinol	Xanthine oxidase inhibitor	50
Apixaban	Factor Xa inhibitor	202
Atorvastatin		50
Azacitidine	Nucleoside metabolic inhibitor	59
Azathioprine	Purine antimetabolite	99
Azithromycin	Macrolide antimicrobial	61
Bamlanivimab		300
Bendamustine		153
Bendamustine hydrochloride	Alkylating drug	103
Bortezomib	Proteasome inhibitor	139
Carboplatin	Platinum-based drug	117
Carfilzomib	Proteasome inhibitor	132
Casirivimab Imdevimab		81
Ceftriaxone	Cephalosporin antibacterial	57
CellCept	Antimetabolite immunosuppressant	70
Cisplatin	Platinum-based drug	97
Comirnaty		77
Cosentyx	Interleukin-17A antagonist	126
Cyclophosphamide	Alkylating drug	484
Cyclosporine	Calcineurin inhibitor immunosuppressant	144
Cytarabine	Nucleoside metabolic inhibitor	96
Daratumumab	CD38-directed cytolytic antibody	179
Darzalex	CD38-directed cytolytic antibody	104
Dexamethasone	Corticosteroid	739
Doxorubicin	Anthracycline topoisomerase inhibitor	212
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	83
Dupixent	Interleukin-4 receptor alpha antagonist	101
Eliquis	Factor Xa inhibitor	119
Enbrel	Tumor necrosis factor blocker	50
Entresto	Angiotensin 2 receptor blocker	84
Etesevimab		78
Etoposide	Topoisomerase inhibitor	143
Everolimus	Kinase inhibitor	72
Fludarabine	Nucleoside metabolic inhibitor	97
Folic acid		52
Furosemide	Loop diuretic	91
Gazyva	CD20-directed cytolytic antibody	84
Gemcitabine	Nucleoside metabolic inhibitor	56
Human immunoglobulin g	Human immunoglobulin G	146
Humira		167
Hydroxychloroquine	Antimalarial	203
Ibrutinib (form s4)	Kinase inhibitor	67
Ifosfamide	Alkylating drug	56
Imbruvica	Kinase inhibitor	135
Indapamide	Thiazide-like diuretic	56
Isatuximab	CD38-directed cytolytic antibody	72
Ixazomib	Proteasome inhibitor	71
Leflunomide	Antirheumatic agent	93
Lenalidomide	Thalidomide analog	383
Levofloxacin	Fluoroquinolone antibacterial	66
Melphalan	Alkylating drug	51
Mepolizumab	Interleukin-5 antagonist	51
Meropenem	Penem antibacterial	64
Methotrexate	Folate analog metabolic inhibitor	404
Methotrexate sodium	Folate analog metabolic inhibitor	96
Methylprednisolone	Corticosteroid	307
Mycophenolate mofetil	Antimetabolite immunosuppressant	576
Mycophenolate sodium		58
Mycophenolic acid	Antimetabolite immunosuppressant	110
Obinutuzumab	CD20-directed cytolytic antibody	209
Ocrelizumab	CD20-directed cytolytic antibody	126
Ocrevus	CD20-directed cytolytic antibody	549
Olanzapine	Atypical antipsychotic	56
Omeprazole	Proton pump inhibitor	76
Oxaliplatin	Platinum-based drug	62
Polatuzumab vedotin		52
Pomalidomide	Thalidomide analog	107
Pomalyst	Thalidomide analog	132
Prednisolone	Corticosteroid	496
Prednisone	Corticosteroid	799
Ramipril	Angiotensin converting enzyme inhibitor	68
Remdesivir	SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	176
Remicade	Tumor necrosis factor blocker	99
Remodulin	Prostacycline vasodilator	52
Revlimid	Thalidomide analog	389
Rinvoq	Janus kinase inhibitor	143
Rituxan	CD20-directed cytolytic antibody	55
Rituximab	CD20-directed cytolytic antibody	1,497
Simponi	Tumor necrosis factor blocker	88
Skyrizi	Interleukin-23 antagonist	71
Sotrovimab		67
Tacrolimus	Calcineurin inhibitor immunosuppressant	634
Tocilizumab	Interleukin-6 receptor antagonist	264
Vedolizumab	Integrin receptor antagonist	56
Veklury	SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	111
Venclexta	BCL-2 inhibitor	87
Venetoclax	BCL-2 inhibitor	172
Vincristine		236
Vincristine sulfate	Vinca alkaloid	73
Xeljanz	Janus kinase inhibitor	143

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 59 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term COVID-19 pneumonia name, in order of name
Class	Reports with this term
Alkylating drug	735
Angiotensin 2 receptor blocker	110
Angiotensin converting enzyme inhibitor	78
Anthracycline topoisomerase inhibitor	298
Anticholinergic	91
Antimalarial	212
Antimetabolite immunosuppressant	801
Antirheumatic agent	111
Atypical antipsychotic	158
BCL-2 inhibitor	259
Benzodiazepine	62
beta-Adrenergic blocker	66
beta2-Adrenergic agonist	61
Biguanide	50
Calcineurin inhibitor immunosuppressant	820
CD20-directed cytolytic antibody	2,610
CD38-directed cytolytic antibody	357
Cephalosporin antibacterial	75
Corticosteroid	2,543
Cytochrome P450 3A inhibitor	84
Endothelin receptor antagonist	77
Factor Xa inhibitor	360
Fluoroquinolone antibacterial	75
Folate analog metabolic inhibitor	525
Histamine-1 receptor antagonist	57
Human immunoglobulin G	206
Insulin analog	59
Integrin receptor antagonist	99
Interleukin-12 antagonist	54
Interleukin-17A antagonist	149
Interleukin-23 antagonist	99
Interleukin-4 receptor alpha antagonist	112
Interleukin-5 antagonist	61
Interleukin-6 receptor antagonist	371
Janus kinase inhibitor	507
Kinase inhibitor	531
Loop diuretic	132
Macrolide antimicrobial	95
Nonsteroidal anti-inflammatory drug	107
Nucleoside metabolic inhibitor	384
Opioid agonist	84
Osmotic laxative	54
Penem antibacterial	66
Platinum-based drug	276
Programmed death Receptor-1 blocking antibody	192
Prostacycline vasodilator	178
Proteasome inhibitor	406
Proton pump inhibitor	256
Purine antimetabolite	149
SARS-CoV-2 nucleotide analog RNA polymerase inhibitor	287
Selective T cell costimulation modulator	86
Sphingosine 1-phosphate receptor modulator	81
Thalidomide analog	1,011
Thiazide-like diuretic	56
Topoisomerase inhibitor	150
Tumor necrosis factor blocker	452
Vascular endothelial growth factor inhibitor	51
Vinca alkaloid	73
Xanthine oxidase inhibitor	50

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record COVID-19 pneumonia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record COVID-19 pneumonia
Age	Reports	Share
Under 2	17	0.1%
2 to 11	68	0.6%
12 to 17	42	0.4%
18 to 44	1,200	10.2%
45 to 64	3,420	29.1%
65 to 74	2,331	19.9%
75 and over	1,803	15.4%
Age not given	2,852	24.3%

Sex of the patient in the reports that record COVID-19 pneumonia
Sex	Reports	Share
Female	5,182	44.2%
Male	5,263	44.9%
Unknown or not given	1,288	11%

Age and sex are as the report gives them. 44% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. COVID-19 pneumonia: adverse event reports that record this term. https://reportedreactions.com/reaction/covid-19-pneumonia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does COVID-19 pneumonia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page